May 10, 2019
Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference
Apr 26, 2019
Mylan to Release First Quarter 2019 Financial Results on May 7, 2019
Apr 24, 2019
Visiongain Report Offers Transformative Insights on the $11.8bn Anaesthesia Drugs Market
Apr 18, 2019
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB)
Apr 10, 2019
GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST 2019-2027
Apr 05, 2019
Global Needle-Free Devices Technologies and Markets Report 2019: 2017-2018 Analysis & CAGR Projections 2019-2023 - Increasing Demand for Painless Drug Delivery
Apr 04, 2019
Visiongain Report: The Global Pharma Contract Sales Market will be Driven by Cost Saving and the Need for More Flexibility
Apr 03, 2019
Striving to Create Better Health for a Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available
Mar 27, 2019
Global COPD Drugs Market by Drug Type, Pipeline Drugs, Region, and Country - Forecast to 2023
Mar 21, 2019
$95.94 Bn Pharmaceutical Contract Manufacturing Market, 2025
Mar 18, 2019
Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter
Mar 07, 2019
SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation
Mar 06, 2019
European CNS Specialist Neuraxpharm Appoints Dan Furrer as Head of Corporate Marketing
Mar 04, 2019
Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029
Feb 25, 2019
Visiongain Report Claims that 30% of the Top Generic Drug Producers are in the ROW Region
Feb 22, 2019
Mylan Launches Generic Suboxone® Sublingual Film to Treat Opioid Dependence
Feb 19, 2019
United States Generic Drug Markets, 2011-2018 & 2019-2024 - Patent Expiry of Blockbuster Drugs & Significant Price Differential between Generics and Innovator Drugs
Feb 12, 2019
Mylan Launches Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand
Feb 11, 2019
Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019
Jan 31, 2019
Mylan Announces FDA Approval of Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)